文献速递血液透析通路

血液透析自体动静脉瘘的年龄相关结局

Age-based outcomes of autogenous fistulas for hemodialysis access.
PubMed 文献 · J Vasc Surg · 2021-07-21

该回顾性队列研究纳入美国肾脏数据系统2007-2014年启动血液透析的303,281例患者,分析年龄与自体动静脉瘘成熟、通畅率及死亡率的关系。结果显示随着年龄增长,自体动静脉瘘成熟率、一期通畅率、一期辅助通畅率、二期通畅率及患者生存率均逐渐下降。作者认为老年患者动静脉通路决策应个体化,综合考虑整体临床状况及替代通路方式的结局。

要点

  • 年龄增长与自体动静脉瘘成熟率下降相关。
  • 5年一期通畅率从<50岁的24%降至80岁以上的18%。
  • 老年患者动静脉通路决策应个体化,权衡整体状况与替代通路结局。

核心结论

  • 在血液透析患者中,随着年龄增长,自体动静脉瘘成熟率、一期通畅率、一期辅助通畅率、二期通畅率及患者生存率均逐渐下降。
  • 尽管老年患者结局相对较差,动静脉通路创建决策应个体化,综合考虑整体临床状况及替代通路方式的结局。

研究设计与样本

  • 回顾性队列研究,纳入美国肾脏数据系统2007-2014年所有启动血液透析的患者,共303,281例。
  • 采用χ2检验、t检验、Kaplan-Meier法、log-rank检验、多变量logistic回归及Cox回归分析评估通路成熟、干预、通畅率及死亡率。

主要发现

  • 48,892例(16.1%)患者年龄<50岁,55,817例(18.4%)为50-59岁,79,138例(26.1%)为60-69岁,75,200例(24.8%)为70-79岁,44,234例(14.6%)为80岁及以上。
  • 5年一期通畅率:<50岁 vs 50-59岁 vs 60-69岁 vs 70-79岁 vs 80岁及以上分别为24% vs 23% vs 21% vs 20% vs 18%(P < .001)。
  • 5年一期辅助通畅率:<50岁 vs 50-59岁 vs 60-69岁 vs 70-79岁 vs 80岁及以上分别为38% vs 40% vs 37% vs 35% vs 33%(P < .001)。
  • 5年二期通畅率:<50岁 vs 50-59岁 vs 60-69岁 vs 70-79岁 vs 80岁及以上分别为48% vs 50% vs 47% vs 45% vs 42%(P < .001)。
  • 风险校正分析显示,随着年龄增长,一期、一期辅助及二期通畅率均逐渐下降;患者生存率随年龄增长而下降。

临床怎么用

  • 对于老年血液透析患者,制定动静脉通路计划时应个体化评估,综合考虑整体临床状况及替代通路方式的结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hemodialysis (HD) dependence and autogenous fistula use for HD span the spectrum of age. This study examines age-related outcomes of autogenous fistulas for HD access in a large population-based cohort of patients. METHODS: A retrospective cohort study of all patients who initiated HD in the United States Renal Database System (2007-2014). χ2 tests, t tests, Kaplan-Meier, log-rank tests, multivariable logistic, and Cox regression analyses were employed to evaluate access maturation, interventions, patency, and mortality. RESULTS: Of the 303,281 patients studied, 48,892 (16.1%) were younger than 50 years, 55,817 (18.4%) were 50 to 59 years, 79,138 (26.1%) were 60 to 69 years, 75,200 (24.8%) were 70 to 79 years, and 44,234 (14.6%) were 80 years or older. There was a decrease in autogenous fistula maturation with increasing age. Primary patency at 5 years comparing patients <50 vs 50 to 59 vs 60 to 69 vs 70 to 79 vs 80+ years was 24% vs 23% vs 21% vs 20% vs 18% (P < .001). Primary assisted patency at 5 years was 38% vs 40% vs 37% vs 35% vs 33% (P < .001). Secondary patency at 5 years was 48% vs 50% vs 47% vs 45% vs 42% (P < .001). The risk-adjusted analyses revealed a progressive decrease in primary, primary assisted, and secondary patency with increasing age. As expected, patient survival decreased with increasing age. CONCLUSIONS: In this population-based cohort of HD patients, there was a decrease in autogenous fistula maturation, primary patency, primary assisted patency, secondary patency, and patient survival with increasing age. Despite the relative decline in outcomes associated with older age, decisions about arteriovenous access creation in older patients should be individualized, taking overall clinical status and outcomes of alternatives modes of access into consideration.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Arhuidese IJ, King RW, Elemuo C, et al. Age-based outcomes of autogenous fistulas for hemodialysis access. J Vasc Surg. 2021. PMID: 34298119. doi:10.1016/j.jvs.2021.06.477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。